Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $40.00 target price on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 130.68% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 price target on shares of Capricor Therapeutics in a research report on Friday, September 20th. Maxim Group raised their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to data from MarketBeat, Capricor Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $22.60.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded down $1.99 during mid-day trading on Wednesday, reaching $17.34. The company had a trading volume of 2,556,669 shares, compared to its average volume of 1,047,744. Capricor Therapeutics has a one year low of $2.68 and a one year high of $21.98. The firm has a market cap of $554.52 million, a price-to-earnings ratio of -20.26 and a beta of 4.01. The business’s 50-day simple moving average is $6.63 and its 200 day simple moving average is $5.84.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The company had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. On average, sell-side analysts anticipate that Capricor Therapeutics will post -1.14 EPS for the current year.

Insider Activity at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were purchased at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 12.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares in the last quarter. Renaissance Technologies LLC boosted its position in Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares during the last quarter. Marshall Wace LLP purchased a new position in Capricor Therapeutics in the second quarter worth $426,000. Bank of New York Mellon Corp boosted its position in Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares during the last quarter. Finally, Rhumbline Advisers purchased a new position in Capricor Therapeutics in the second quarter worth $147,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.